Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 4/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492244 | 0.92 | PPARG (0.46) | PPARGALOX5APBCL2MCL1 | |
| SCHEMBL6501700 | 0.91 | MCL1 (0.40) | PPARGALOX5APMAPTALDH1A1LMNA | |
| SCHEMBL6488086 | 0.87 | ALOX5AP (0.42) | PPARGALOX5APMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6488597 | 0.85 | BCL2 (0.50) | PPARGALOX5APBCL2MCL1 | |
| SCHEMBL6308646 | 0.85 | PPARG (0.56) | PPARGALOX5APMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6304029 | 0.84 | PPARG (0.55) | PPARGALOX5APMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6307980 | 0.84 | PPARG (0.55) | PPARGALOX5APMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6488725 | 0.83 | ALOX5AP (0.37) | PPARGALOX5APMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6497461 | 0.83 | PPARG (0.49) | PPARGALOX5APMAPTALDH1A1LMNA | |
| SCHEMBL6500673 | 0.83 | PPARG (0.49) | PPARGALOX5APMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885ALOX5AP 4663/4885MAPT 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.